All In Biotech

Drug Trial Radar · NCT04936529

A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma

Phase II Trial of a Bivalent Vaccine With the Immunological Adjuvant OPT-821 (QS-21), in Combination With Oral β-glucan and Randomization of GM-CSF, for High-risk Neuroblastoma

Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 286 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

286

Planned (sponsor's estimate)

Start

Aug 2, 2021

Primary completion

Jun 15, 2027

Study completion Jun 15, 2027

Sponsor

Lead sponsor
Memorial Sloan Kettering Cancer CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 23, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Factorial
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of the study is to explore the combination of a bivalent vaccine, a sugar called beta-glucan (β-glucan), and a protein called granulocyte-macrophage colony stimulating factor (GM-CSF) as an effective treatment for people with high-risk neuroblastoma that is in complete remission. The combination may be effective because the different parts of the treatment work to strengthen the immune system's response against cancer cells in different ways.

Conditions

  • Neuroblastoma

Interventions

  • β-glucanDietary supplement

    Group 1 participants receive oral β-glucan (40 mg/kg/day) starting week 1 and continue with \~2 weeks on, \~2 weeks off, up to 1 cycle after vaccination #7, then 1 cycle with each subsequent vaccination (#8-#14). This schedule includes annual booster vaccinations, with a 2-week cycle of β-glucan, administered at months 36 (3 years), 48 (4 years), and 60 (5 years). Group 2 participants receive oral β-glucan (40 mg/kg/day) starting week 1 and continue with \~2 weeks on, \~2 weeks off, up to 1 cycle after vaccination #7, then 1 cycle with each subsequent vaccination (#8-#14). Group 3 participants will be treated as in Group 1.

  • GM-CSFDrug

    Group 1 participants will not receive GM-CSF. Group 2 participants will receive GM-CSF (250 mcg/m2/day) x3 days with vaccinations #1-#3; x7 days with vaccinations #4-#11; and x5 days with vaccinations #12-#14. Group 3 participants will be treated as in Group 1.

  • OPT-821Biological

    Vaccine injections must occur a minimum of 6 days apart. After the first four vaccine injections, vaccines can be administered up to two weeks earlier or later than indicated without representing a protocol violation.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Effect of GM-CSF on anti-GD2 antibody titersTime frame: 32 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.